biostudies-literatureUnknown14(10)Wu Y<h4>Background</h4>Crow's feet lines (CFLs) can impact the emotional state, self-perception, and consciousness regarding appearance of patients.<h4>Objective</h4>This study sought to assess patient-reported outcomes after onabotulinumtoxinA treatment for CFLs among Chinese subjects.<h4>Methods</h4>A five-month, double-blind, randomized, parallel-group, placebo-controlled Phase III clinical study was conducted including Chinese adults with moderate-to-severe CFLs at maximum smile. Subjects were randomized 3:1 to 24 U of onabotulinumtoxinA or placebo and completed the 11-item Facial Line Outcomes (FLO-11) questionnaire and Facial Line Satisfaction Questionnaire (FLSQ) at baseline; on Days 8, 15, and 30; and monthly thereafter until Day 150. Item-level and/or domain analyses for the FLO-11 and FLSQ were conducted.<h4>Results</h4>Of 417 treated subjects, 316 received onabotulinumtoxinA and 101 received placebo. For all 10 validated stand-alone FLO-11 items, there was a significantly greater proportion of responders in the onabotulinumtoxinA group versus placebo (<i>P</i><0.001) at Day 30 that was maintained through Day 150. Significant improvements at Day 30 were reported for all FLSQ items and the FLSQ Follow-up Impact Domain (<i>P</i>≤0.01).<h4>Conclusion</h4>FLO-11 and FLSQ data indicated high satisfaction and significant improvements in appearance-related and emotional impacts through Day 150 in patients treated with onabotulinumtoxinA for moderate-to-severe CFLs in Chinese subjects.<h4>Trial registration</h4>ClinicalTrials.gov identifier no. NCT02195687.The Journal of clinical and aesthetic dermatology27-31https://www.ebi.ac.uk/biostudies/studies/S-EPMC8711615biostudies-literaturePatient-reported Outcomes in Chinese Subjects Treated with OnabotulinumtoxinA for Crow's Feet Lines.PMC8711615Garcia JLi CBaradaran SWu YfalsePatient-reported Outcomes in Chinese Subjects Treated with OnabotulinumtoxinA for Crow's Feet Lines.<h4>Background</h4>Crow's feet lines (CFLs) can impact the emotional state, self-perception, and consciousness regarding appearance of patients.<h4>Objective</h4>This study sought to assess patient-reported outcomes after onabotulinumtoxinA treatment for CFLs among Chinese subjects.<h4>Methods</h4>A five-month, double-blind, randomized, parallel-group, placebo-controlled Phase III clinical study was conducted including Chinese adults with moderate-to-severe CFLs at maximum smile. Subjects were randomized 3:1 to 24 U of onabotulinumtoxinA or placebo and completed the 11-item Facial Line Outcomes (FLO-11) questionnaire and Facial Line Satisfaction Questionnaire (FLSQ) at baseline; on Days 8, 15, and 30; and monthly thereafter until Day 150. Item-level and/or domain analyses for the FLO-11 and FLSQ were conducted.<h4>Results</h4>Of 417 treated subjects, 316 received onabotulinumtoxinA and 101 received placebo. For all 10 validated stand-alone FLO-11 items, there was a significantly greater proportion of responders in the onabotulinumtoxinA group versus placebo (<i>P</i><0.001) at Day 30 that was maintained through Day 150. Significant improvements at Day 30 were reported for all FLSQ items and the FLSQ Follow-up Impact Domain (<i>P</i>≤0.01).<h4>Conclusion</h4>FLO-11 and FLSQ data indicated high satisfaction and significant improvements in appearance-related and emotional impacts through Day 150 in patients treated with onabotulinumtoxinA for moderate-to-severe CFLs in Chinese subjects.<h4>Trial registration</h4>ClinicalTrials.gov identifier no. NCT02195687.2021-01-01T00:00:00Z2021 Oct2025-04-03T22:46:19.089Z2022-02-11T14:44:26.505ZS-EPMC871161534976286